Kornimate/medical-research-clean huggingface dataset:
a phase iv study of cipro xr in uncomplicated uti

Conditions: Urinary Tract Infections

Summary: safety and efficacy of cipro xr in a naturalistic setting and the effectiveness of an educational brochure. - women with urinary tract infections were treated with cipro xr. they were also given a brochure with information about urinary tract infections and later tested on the information.


Eligibility criteria:
inclusion criteria: * ambulatory women outpatients 18 to 65 years of age with a documented clinical diagnosis of uuti characterized by dysuria with either urgency or frequency. women of childbearing age were enrolled only if they were highly unlikely to conceive during the study and were practicing a suitable method of birth control or were at least 1 year postmenopausal. * positive leukocyte esterase (\>/= 1+) and positive nitrite test using a urine dipstick method of analysis. * willing to give written consent. exclusion criteria: * pregnant or nursing * complicated uti * allergy to cipro xr

Keywords: uti
influence of skeletal muscle paralysis on metabolism in hypothermic patients after cardiac arrest

Conditions: Critical Illness; Cardiac Arrest

Summary: the purpose of this study is to evaluate the impact of muscle relaxing drugs on the energy rate during hypothermia after cardiac arrest.

mild hypothermia improves neurological outcome after cardiac arrest. neuromuscular blockers are in use, together with analgesia and sedation, during the cooling process in many centers to prevent shivering. however, neuromuscular blockers are accused to be associated with various side effects causing serious harm and/or leading to prolonged icu stay. furthermore, the use of neuromuscular blockers may mask epileptic activity. therefore, the advantages and disadvantages of neuromuscular blockers during therapeutic hypothermia need to be re-evaluated. aim of this study is to investigate if continuous application of neuromuscular blockers is necessary to prevent shivering and thereby avoiding an increase in energy expenditure in patients during therapeutic hypothermia and rewarming after cardiac arrest (initial 72h).

Eligibility criteria:
inclusion criteria: * all patients receiving mild therapeutic hypothermia after cardiac arrest of presumed cardiopulmonary origin exclusion criteria: * age \< 18 * cardiac arrest \>6 hours before admittance at the hospital * patients with known or clinically apparent pregnancy * patients who reach our hospital with a body temperature below 35°c * patients with known allergic reactions against rocuronium * patients with a history of myasthenia gravis * patients with obvious intoxication * wards of the state/prisoners * patients with known epileptic disease
ex vivo human thrombosis chamber study

Conditions: Cardiovascular Disease

Summary: purpose of study is to evaluate a thrombosis chamber model


Eligibility criteria:
inclusion criteria: * healthy subjects * bmi 18-30 kg/m² * male ages 18-45 exclusion criteria: * significant acute or chronic illness * history of abnormal bleeding or coagulation disorder, intracranial hemorrhage, or a family history of abnormal bleeding or coagulation disorder in a first degree relative under 50 years of age * easy bruising * smoking within 3 months prior to day 1
monitoring of patients followed for a multiple sclerosis and treated by dimethyl-fumarate

Conditions: Multiple Sclerosis, Relapsing-Remitting

Summary: the dimethyl fumarate is an oral drug, indicated in the treatment of the relapsing-remitting multiple sclerosis (ms) , which efficacy and safety has been assessed and validated in two randomised, placebo phase-controlled iii international studies, organized by the pharmaceutical company developing the molecule. tecfidera® (dimethyl-fumarate) has received european approval on january 30, 2014, for the treatment of adult patients with relapsing remitting ms. treatment with dimethyl fumarate is introduced as part of the usual care under supervision of a physician experienced in the treatment of the disease. it has proved effective to reduce the number of relapses in patients with recurring-remitting ms and reduce the number of patients who have relapses during treatment. the objective of the study is to observe, in real conditions, on the one hand the tolerance and the other evolution, clinical and radiologic disease in patients already treated by dimethyl-fumarate and collect long-term safety data.


Eligibility criteria:
inclusion criteria: * patient 18 years old and more * with multiple sclerosis according to the criteria of mac donald 2010 : relapsing-remitting (rr), secondary-progressive (sp) or primary-progressive (pp) * for which treatment with dimethyl-fumarate has been prescribed * followed at the rothschild foundation in the neurology department * having given written consent to participation in the study exclusion criteria: * pregnant or breastfeeding woman * patient with a measure of legal protection * subject unaffiliated insurance

Keywords: multiple sclerosis, relapsing-remitting dimethyl fumarate
estimating the use of resources and the costs of treating patients with asthma in the autonomous community of valencia

Conditions: Asthma; Valencia Autonomous Region

Summary: this study has been conceived in the context of health outcomes research where the outcomes of health interventions in routine clinical practice constitute the main objective of the research process. in the case of asthma in spain, the investigators do not clearly know the use of resources generated by the patient with asthma, its impact on the effectiveness of the current approach of asthmatic patients and the overall efficiency of health interventions on asthmatic patients. this observational, retrospective and multicenter study aims to estimate the use of health care resources in managing patients with asthma and to determine the management of the disease in the usual clinical practice in valencia autonomous region. the data will be obtained at primary care level from the electronic health record sia+gaia data base and at hospital level from allergologists and pneumologists clinical records. the investigators plan to introduce 289 ambulatory patients followed-up in primary or specialized care services, older than 15 years of age, diagnosed of asthma at least one year before the beginning of the study. the inclusion period will be of 3 months and the retrospective data of 12 previous months of follow-up will be collected. the direct and indirect use of resources will be collected in order to estimate the management and use of health care resources in managing patients with asthma in the autonomous region of valencia as primary endpoint and also to estimate the mean cost of asthmatic patient healthcare; to determine the global effectiveness and the efficiency of the actual asthmatic patient healthcare and to model the health budget according to different objectives of effectiveness for the next five years.


Eligibility criteria:
inclusion criteria: * ambulatory patients (primary and specialized care) * patients with a diagnose of asthma in the outpatients' electronic health record \[historia clínica ambulatoria electrónica (sia + gaia) database exclusion criteria: * patients who have participated in a clinical trial in the last 12 months.

Keywords: asthma resource use
pea promote gastrointestinal function recovered after colorectal cancer operation

Conditions: Colorectal Cancer

Summary: to investigate whether perioperative electroacupuncture is more effective than postoperative electroacupuncture in improving gastrointestinal function after colorectal cancer operation

although there are large intestine cancer postoperative clinical research of acupuncture, but fewer sample size, whether perioperative acupuncture intervention is superior to the postoperative acupuncture intervention, remains to be seen, so investigators proposed to carry out the preliminary experiment, the data can be collected according to the different characteristics of perioperative, perioperative choose different acupoints compatibility, give full play to the needle medicine compound anesthesia in colorectal cancer surgery play a unique function of viscera protection, to explore the curative in colorectal cancer surgery perioperative intervened to promote the role of gastrointestinal function after surgery for early rehabilitation provides evidence-based medical evidence, develop and optimize the acupuncture and drugs combined anesthesia in colorectal cancer surgery perioperative application of specification, it promoted the establishment of the first treatment mode of "accelerated recovery in perioperative period of colorectal cancer operation based on combined acupuncture and drug anesthesia"

Eligibility criteria:
inclusion criteria: 1. patients who meet the diagnostic criteria of colorectal cancer and need elective radical resection of colorectal cancer; 2. 18≤ age≤79, gender is not limited; 3. understand and agree to participate in the study and sign the informed consent; 4. no previous history of abdominal surgery and no abdominal adhesion; exclusion criteria: 1. patients with mental illness; 2. patients requiring combined resection of other organs; 3. participated in or is participating in other clinical researchers in the previous 3 months 4. people who have received acupuncture (including electroacupuncture) in the past; 5. other treatment options are being used (chemotherapy, radiotherapy, etc.) those who meet any of the above criteria will be excluded from the study.

Keywords: electroacupuncture eras gastrointesinal function
comparison of the effects of bevacizumab before vs after pattern panretinal photocoagulation

Conditions: Macular Edema

Summary: compare the effect of an intravitreal injection of bevacizumab previous or posterior of panretinal laser photocoagulation (prlp) with a pattern laser; to prevent and reduce diabetic macular edema (dme) in patients with proliferative diabetic retinopathy (pdr) with dme.


Eligibility criteria:
inclusion criteria: * patients with proliferative diabetic retinopathy * patients with macular edema exclusion criteria: * patients with previous treatments * patients with ocular surgeries

Keywords: intravitreal injection of bevacizumab visual acuity central retinal thickness color studies, farnsworth-munsell electroretinogram studies
post covid19 functional and cognitive assessments

Conditions: Covid19; Respiratory Disease; Walking, Difficulty; Cognitive Decline

Summary: the main objective of the proposed study is to evaluate the impact of coronavirus (2019-ncov), hereafter covid -19, on patients' loss of functional capacity after completion of hospital treatment. specifically, the research will focus on examining changes in musculoskeletal, cardiovascular, and respiratory function, as well as motor control. in addition, we aim to evaluate rehabilitation treatments after recovery from covid -19 and consider additional preventive measures based on previous experience.

the combination of such a severe respiratory disease as covid -19 with motor inactivity could have very serious consequences for a person's general health even after covid -19 symptoms have subsided. to date, the effects of covid -19 on individual muscle status have not been extensively studied. therefore, the main objective of this study will be to evaluate the muscle status of patients after covid -19. in addition, we will be interested in longitudinal monitoring of individuals' rehabilitation, where they will receive instructions based on measured outcomes at hospital discharge. we will also be interested in considering additional preventive measures for future patients based on previous experience of infected and hospitalized covid -19 patients.

Eligibility criteria:
inclusion criteria: * completed hospital treatment after a positive covid-19 test * signed written consent exclusion criteria: * still testing positive for covid -19 at discharge. * severe musculoskeletal injuries (e.g., disability). * inability to follow instructions when performing the test.

Keywords: covid19 functional outcomes respiratory function
oxaliplatin and fluorouracil in treating patients with recurrent ovarian cancer

Conditions: Ovarian Cancer

Summary: rationale: drugs used in chemotherapy use different ways to stop tumor cells from dividing so they stop growing or die. combining more than one drug may kill more tumor cells. purpose: phase ii trial to study the effectiveness of combining oxaliplatin and fluorouracil in treating patients who have recurrent ovarian cancer.

objectives: i. determine the efficacy of oxaliplatin in combination with fluorouracil in terms of response rate, time to tumor progression, and overall survival in patients with recurrent ovarian cancer. ii. evaluate the safety profile of this combination regimen in this patient population. outline: this is an open label study. patients receive oxaliplatin iv over 2 hours once every 2 weeks and fluorouracil iv and leucovorin calcium iv once weekly. treatment repeats every 2 weeks for 12 courses in the absence of disease progression or unacceptable toxicity. patients with stable or responding disease are followed at 1 month and at 3 months, then every 3 months for disease relapse and survival. projected accrual: a total of 14-50 patients will be accrued for this study within 2 years.

Eligibility criteria:
disease characteristics: histologically confirmed ovarian cancer must have received at least one prior platinum based chemotherapy regimen and have relapsed within 2 years of last chemotherapy regimen evaluable disease radiology confirmation and/or elevated ca 125 (at least 60 iu/l) patient characteristics: age: 18 and over performance status: ecog 0-2 life expectancy: at least 12 weeks hematopoietic: absolute neutrophil count at least 1,500/mm3 platelet count at least 100,000/mm3 hemoglobin at least 9.0 g/dl hepatic: bilirubin less than 1.5 times upper limit of normal (uln) (unless documented gilbert's syndrome) ast/alt less than 3 times uln (less than 5 times uln if liver metastases present) renal: creatinine normal cardiovascular: no unstable cardiovascular disease other: no active, uncontrolled infection no other significant medical disorder or condition that would preclude study no other malignancy within the past 5 years except curatively treated nonmelanoma skin cancer or carcinoma in situ of the cervix not pregnant or nursing negative pregnancy test fertile patients must use effective contraception prior concurrent therapy: biologic therapy: no concurrent immunotherapy chemotherapy: see disease characteristics at least 4 weeks since prior chemotherapy no other concurrent chemotherapy endocrine therapy: not specified radiotherapy: at least 3 weeks since prior radiotherapy and recovered surgery: not specified other: at least 30 days since prior investigational agents

Keywords: recurrent ovarian epithelial cancer
effect of oral sildenafil citrate on improvement of endometrial thickness

Conditions: Infertility, Female

Summary: one hundred thirty women with unexplained infertility participated in a prospective clinical study. patients were assigned at random to one of two groups. the first group (n=65) served as the study group and was given clomiphene citrate 50 mg (tecnovula®, techno pharmaceuticals, egypt) and sildenafil (respatio®, pharma right group, egypt) 20 mg tablets. the second group (n=65) served as a control and received a placebo tablet in addition to the standard treatment of clomiphene citrate 50 mg (tecnovula®). a transvaginal ultrasound was performed on all of the patients to assess ovulation.

one hundred thirty women with unexplained infertility participated in a prospective clinical study. patients were assigned at random to one of two groups. the first group (n=65) served as the study group and was given clomiphene citrate 50 mg (tecnovula®, techno pharmaceuticals, egypt) orally twice daily from the second day of their cycle through the seventh day and sildenafil (respatio®, pharma right group, egypt) 20 mg tablets from the end of menstruation through ovulation. the second group (n=65) served as a control and received a placebo tablet in addition to the standard treatment of clomiphene citrate 50 mg (tecnovula®). a transvaginal ultrasound was performed on all of the patients to assess ovulation, follicle count, and pregnancy. consequences, including miscarriage, ectopic pregnancy, and multiple pregnancies, were monitored.

Eligibility criteria:
inclusion criteria: * ages of 18 to 40 * patent tubes * unexplained infertility * regular menstrual cycle * husband with normal sperm parameters exclusion criteria: * hypotension * cardiovascular, renal and hepatic diseases * uncontrolled diabetes mellitus * anovulatory infertility * abnormal thyroid functions * ovarian cysts * patients taking nitrates * pelvic adhesions * abnormal hormonal profile. * hyperprolactinemia * multiple uterine fibroids * adenomyosis and endometriosis suspicion
study of clofarabine in combination with low dose cytarabine to treat myelodysplastic syndromes

Conditions: Myelodysplastic Syndromes

Summary: this is an interventional, multicenter, open label, phase ii study designed to evaluate the safety and efficacy of clofarabine in combination with low dose cytarabine in untreated patients with poor risk of myelodisplastic syndromes.


Eligibility criteria:
inclusion criteria: * male and female patients age 55 to 80 years * written informed consent to participate in the clinical trial * morphologically confirmed diagnosis of mds according to who classification, and ipss int-2 or high risk according to ipss index * ecog performance status 0-2 * no previous chemotherapy * serum bilirubin ≤1.5 times upper limit of normal (uln) (unless elevation is due primarily to elevated unconjugated hyperbilirubinemia secondary to gilbert's syndrome or hemolysis, but not to liver dysfunction) * ast and alt ≤2.5 times uln * alkaline phosphatase ≤2.5 times uln * serum creatinine ≤ 1 mg/dl: if serum creatinine \> 1.0 mg/dl, then the estimated glomerular filtration rate (gfr) must be \>60 ml/min/1.73 m2 as calculated by the modification of diet in renal disease equation where predicted gfr (ml/min/1.73 m2) = 186 x (serum creatinine) -1.154 x age in years -0-023 x 0.742 (if patient is female) x 1.212 (if patient is black) * hiv negative exclusion criteria: * have had any other chemotherapy or any investigational therapy as a treatment for mds. patients who received chemotherapy for other cancers than mds/aml can be enrolled, provided that at least 6 months elapsed from accomplishment of the last course of chemo. * have had a prior hematopoietic stem cell transplant for mds * have an uncontrolled systemic fungal, bacterial, viral, or other infection (defined as exhibiting ongoing signs/symptoms related to the infection and without improvement, despite appropriate antibiotics or other treatment). * have a psychiatric disorder that would interfere with consent, study participation, or follow-up. * have any other severe concurrent disease, or have a history of serious organ dysfunction or disease involving the heart * have had any prior treatment with clofarabine * have had a diagnosis of another malignancy, unless the patient has been disease-free for at least 3 years following the completion of curative intent therapy with the following exceptions: a.)patients with treated non-melanoma skin cancer, in situ carcinoma, or cervical intraepithelial neoplasia, regardless of the disease -free duration, are eligible for this study if definitive treatment for the condition has been completed. b.)patients with organ-confined prostate cancer with no evidence of recurrent or progressive disease based on prostate-specific antigen (psa) values are also eligible for this study if hormonal therapy has been initiated or a radical prostatectomy has been performed. * have prior positive test for the human immunodeficiency virus (hiv), hcv, hbv.

Keywords: myelodysplastic syndromes clofarabine low dose cytarabine poor risk mds
tissue sample study for mitochondrial disorders

Conditions: Mitochondrial Disorders; Mitochondrial Disease; Melas; Kearns Sayer; NARP; MNGIE; LHON; Mitochondrial Depletion Syndrome; Leigh's Disease

Summary: the investigators are studying patients with undefined mitochondrial diseases to identify genetic mutations in nuclear or mitochondrial deoxyribonucleic acid (dna). most patients with suspected or known mitochondrial diseases have no genetic confirmation. the investigators expect that evaluating tissue samples from patients with mitochondrial disorders will lead us to discover mutations in new or known genes causing mitochondrial dysfunction.

presently, the investigators know of about 200 mitochondrial disorders. the investigators know that there are about 1,300 genes responsible for mitochondrial function. thus, there are a lot of mutated genes to be discovered out there. currently, most patients with suspected or known mitochondrial disorders do not have genetic confirmation of the disease. the goal of this project is to perform biochemical and dna analysis on tissue samples of patients with mitochondrial disorders to find new genes that might be involved in mitochondrial dysfunction. leftover patient tissue samples will be obtained for analysis from within the columbia presbyterian medical center. left over patient samples may also be sent from outside the institution. this is not a "first-step" in the diagnostic process, but rather an option for evaluation in patient samples for which no known diagnosis or genetic confirmation has been made. the research laboratory does not guarantee that a sample will be analyzed. sample analysis is performed according to research interest. if they choose, patients can be contacted should laboratory findings provide insight into their disease.

Eligibility criteria:
inclusion criteria: * patients suspected of having a mitochondrial disorder * patients who may carry a genetic mutation or be related to someone with a genetic mutation which may cause a mitochondrial disorder exclusion criteria: * patients who are not suspected of having a mitochondrial disorder

Keywords: mitochondrial disorder mitochondria oxidative phosphorylation oxidative phosphorylation disorders respiratory chain disorders mitochondrial disease melas kearns sayer narp mngie lhon mitochondrial depletion syndrome leigh's disease